Product nameAnti-PAR2 antibody
See all PAR2 primary antibodies
DescriptionRabbit polyclonal to PAR2
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Chimpanzee, Gorilla, Orangutan
Synthetic peptide corresponding to Human PAR2 aa 1-100 conjugated to keyhole limpet haemocyanin.
Database link: P55085
- This antibody gave a positive signal in Human Liver tissue lysate. This antibody gave a positive result in IHC in the following FFPE tissue: Human colon adenocarcinoma
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab138479 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 45 kDa (predicted molecular weight: 44 kDa).|
|IHC-P||Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionReceptor for trypsin and trypsin-like enzymes coupled to G proteins that stimulate phosphoinositide hydrolysis. May have a role in the regulation of vascular tone.
Tissue specificityWidely expressed in tissues with especially high levels in pancreas, liver, kidney, small intestine, and colon. Moderate expression is detected in many organs, but none in brain or skeletal muscle.
Sequence similaritiesBelongs to the G-protein coupled receptor 1 family.
modificationsA proteolytic cleavage generates a new N-terminus that functions as a tethered ligand.
Cellular localizationCell membrane.
- Information by UniProt
- Coagulation factor II receptor like 1 antibody
- Coagulation factor II receptor-like 1 antibody
- Coagulation factor II thrombin receptor like 1 antibody
IHC image of PAR2 staining in Human colon adenocarcinoma formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab138479, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Anti-PAR2 antibody (ab138479) at 1 µg/ml (Milk blocking 3%) + Liver (Human) Tissue Lysate - adult normal tissue at 20 µg
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 44 kDa
Observed band size: 45 kDa why is the actual band size different from the predicted?
Exposure time: 30 seconds
PAR2 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
This blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% Milk before being incubated with ab138479 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
This product has been referenced in:
- Hoffman S et al. Fecal Proteases from Pouchitis Patients Activate Protease Activating Receptor-2 to Disrupt the Epithelial Barrier. J Crohns Colitis N/A:N/A (2019). Read more (PubMed: 31056700) »
- Zhang Y et al. Therapeutic effect of protease-activated receptor 2 agonist SLIGRL-NH2 on loperamide-induced Sprague-Dawley rat constipation model and the related mechanism. Drug Des Devel Ther 12:2403-2411 (2018). Read more (PubMed: 30122898) »